Gabriele Multhoff

Gabriele Multhoff is Professor of Experimental Radiation Oncology and Radiobiology in the Department of Radiation Oncology at the Technische Universität München (TUM) and Head of the Radiation Immuno-Oncology Research Group at the TranslaTUM – Central Institute for Translational Cancer Research at TUM, Munich, Germany. Gabriele Multhoff is also Founder, former CEO and current CSO of Multimmune GmbH, Munich, Germany, a private clinical-stage biopharmaceutical company. In 2002 she became a Professor of Experimental Hematology at the University Hospital Regensburg. For more than 15 years, Gabriele Multhoff has focused on the development of innovative NK cell-based immunotherapies, therapeutic antibodies and targeting nanoparticles based on selective expression of heat shock proteins. At the TU München, Gabriele Multhoff initiated a proof-of-concept phase II clinical trial to evaluate an NK cell mediated immunotherapeutic approach based on heat shock proteins (HSP) to improve the clinical outcome of NSCLC patients following radio(chemo)therapy. Gabriele Multhoff’s research group is also identifying tumor-specific biomarkers for multimodal tumor imaging and theranostic purposes. Gabriele Multhoff has over 200 papers in peer-reviewed journals and is a named inventor on over 10 filed patents.